Sep 18, 2026•3 min read
FDA Grants Priority Approval to EPIZYME’s Orphan Drug TAZVERIK (TAZEMETOSTAT HYDROBROMIDE 200 mg)
The FDA approved TAZVERIK, a prescription oral tablet for EPIZYME Inc., under NDA 213400 with priority review and orphan designation.